TILT Holdings Announces Pending Delisting from Cboe Canada

TILT Holdings Announces Pending Delisting from Cboe Canada GlobeNewswire November 14, 2025 SCOTTSDALE Ariz., Nov. 14, 2025 (GLOBE NEWSWIRE) — TILT Holdings Inc. (“TILT” or the “Company”) (Cboe CA: TILT) (OTCID: TLLTF), a global provider of cannabis business solutions including inhalation technologies, cultivation, manufacturing, processing, brand development and retail, announced that, following its announcement on […]

Prairie Provident Announces Third Quarter 2025 Results

(TSX:PPR), CALGARY, Alberta, Nov. 14, 2025 (GLOBE NEWSWIRE) — Prairie Provident Resources Inc. (“Prairie Provident” or the “Company”) (TSX:PPR) announces its financial and operating results for the third quarter of 2025. The Company's interim financial statements for the three and nine months ended September 30, 2025 and related Management's Discussion and Analysis (“MD&A”) are available

Prairie Provident Announces Third Quarter 2025 Results

Prairie Provident Announces Third Quarter 2025 Results GlobeNewswire November 14, 2025 CALGARY, Alberta, Nov. 14, 2025 (GLOBE NEWSWIRE) — Prairie Provident Resources Inc. (“Prairie Provident” or the “Company”) (TSX:PPR) announces its financial and operating results for the third quarter of 2025. The Company's interim financial statements for the three and nine months ended September 30,

Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities

Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities GlobeNewswire November 14, 2025 NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) — Waldencast plc, (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that it had sold its

Micro Medical Solutions Expands Board of Directors with Appointment of Vince Burgess and John Dahldorf

Micro Medical Solutions (MMS), an innovative medical device company focused on improving outcomes for patients suffering fromCritical Limb Threatening Ischemia (CLTI), today announced the appointment ofVince BurgessandJohn Dahldorfto itsBoard of Directors. They joinGeorge Quinoy, Chairman of the Board and President & Chief Executive Officer, andDr. Ron Solar, Board Member, as MMS strengthens its leadership team

Sol Strategies Announces Filing of Corrective Disclosure

SOL Strategies Inc. (NASDAQ:STKE) (CSE:HODL) (“SOL Strategies” or the “Company”), a publicly traded Canadian company focused on investing in and providing infrastructure for theSolana blockchain ecosystem, today announced that the Company has refiledonSEDAR+its interim unaudited condensed financial statements for the three and nine months ended June 30, 2025 and 2024 (the “Q3 Financial Statements”). TheQ3FinancialStatementswererefiledtocorrecterrors

XTI Aerospace Announces Rescheduled Town Hall Addressing Strategic Initiatives

Updates on XTI Aircraft Program, Drone Nerds Acquisition, and Strategic Investment from Unusual Machines XTI Aerospace, Inc. (“XTI” or the “Company”) [NASDAQ: XTIA], a leader in scalable vertical-flight technologies and developer of the TriFan 600 next-generation vertical takeoff and landing (VTOL) aircraft, announced today that it will host a Town Hall event for investors, analysts,

OMNIQ Reports Third Quarter Financial Results

(Other OTC:OMQS),(OTC US:OMQS), SALT LAKE CITY, Nov. 14, 2025 (GLOBE NEWSWIRE) — OMNIQ Corp (OTCMTS: OMQS or “omniQ” or “the Company”) today announced its financial results for the third quarter 2025. The company reported $8.8 million in revenue and $3 million gross profit. The company continues to implement its cost-reduction strategy designed to strengthen profitability

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

(NASDAQ:BNTC), –Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301- -Positive interim clinical study results from the Phase 1b/2a trial of BB-301, showed a 100% responder rate, with all six patients

Scroll to Top